PARLIAMENTARY WRITTEN QUESTION
Odevixibat (24 November 2021)
Question Asked
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of Odevixibat for treating processive familial intrahepatic cholestasis.
Asked by:
Jesse Norman (Conservative)
Asked by:
Jesse Norman (Conservative)
Answer
The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether licenced medicines represent a clinically and cost-effective use of resources.
NICE is currently appraising odevixibat for the treatment of progressive familial intrahepatic cholestasis through its highly specialised technologies programme and expects to publish final guidance in January 2022.
Answered by:
Edward Argar (Conservative)
2 December 2021
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.